For instance, the upregulation of PD-L1 has been associated with increase resistance to cisplatin in patients with small cell lung cancer [48], and resistance to BRAF inhibitors in patients with metastatic melanoma is similarly linked to PD-L1 [49]. Here, BRAF is linked to small cell lung carcinoma.